Selexipag Patent Expiration

Selexipag is Used for treating pulmonary arterial hypertension. It was first introduced by Actelion Pharmaceuticals Us Inc in its drug Uptravi on Dec 21, 2015. 3 different companies have introduced drugs containing Selexipag.


Selexipag Patents

Given below is the list of patents protecting Selexipag, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Uptravi US10821108 Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide Dec 01, 2036 Actelion
Uptravi US10828298 Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide Dec 01, 2036 Actelion
Uptravi US7205302 Heterocyclic compound derivatives and medicines Oct 31, 2026 Actelion
Uptravi US8791122 Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide and method for producing the same Aug 01, 2030 Actelion
Uptravi US9173881 Therapeutic compositions containing macitentan Aug 12, 2029 Actelion
Uptravi US9284280 Use of form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide Jun 25, 2030 Actelion


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳

Selexipag Generics

Several generic applications have been filed for Selexipag. The first generic version for Selexipag was by Zydus Lifesciences Global Fze and was approved on Dec 21, 2022. And the latest generic version is by Alembic Pharmaceuticals Ltd and was approved on Oct 11, 2023.

Given below is the list of companies who have filed for Selexipag generic.


1. ZYDUS LIFESCIENCES

Zydus Lifesciences Global Fze has filed for 8 different strengths of generic version for Selexipag. Given below are the details of the strengths of this generic introduced by Zydus Lifesciences.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2MG tablet Discontinued ORAL N/A Dec 21, 2022
0.4MG tablet Discontinued ORAL N/A Dec 21, 2022
0.6MG tablet Discontinued ORAL N/A Dec 21, 2022
0.8MG tablet Discontinued ORAL N/A Dec 21, 2022
1MG tablet Discontinued ORAL N/A Dec 21, 2022
1.2MG tablet Discontinued ORAL N/A Dec 21, 2022
1.4MG tablet Discontinued ORAL N/A Dec 21, 2022
1.6MG tablet Discontinued ORAL N/A Dec 21, 2022


2. ALEMBIC

Alembic Pharmaceuticals Ltd has filed for 6 different strengths of generic version for Selexipag. Given below are the details of the strengths of this generic introduced by Alembic.

Strength Dosage Form Availability Application Pathway TE code Launch Date
0.2MG tablet Prescription ORAL AB Oct 11, 2023
0.4MG tablet Prescription ORAL AB Oct 11, 2023
0.6MG tablet Prescription ORAL AB Oct 11, 2023
0.8MG tablet Prescription ORAL AB Oct 11, 2023
1.4MG tablet Prescription ORAL AB Oct 11, 2023
1.6MG tablet Prescription ORAL AB Oct 11, 2023